Ophthalmology Amniotic Membrane Market Size
Ophthalmology Amniotic Membrane Market size was valued at USD 427.76 million in 2025 and excepted to reach 994.77 million by 2033 is estimated to reach at a CAGR of 10.22 % over the forecast period 2026-2033.
The ophthalmology amniotic membrane market is centered on using natural amniotic membranes to treat different eye problems, such as dry eye disease, corneal ulcers, chemical burns, and surgical repairs. These membranes possess anti-inflammatory, anti-scarring, and regenerative properties, making them highly effective in promoting healing and tissue repair in ophthalmic applications.
Market growth is driven by the increasing prevalence of eye disorders, rising demand for advanced wound care solutions, and growing adoption of regenerative therapies in ophthalmology. Additionally, the expansion of outpatient surgical procedures and increasing awareness among ophthalmologists regarding the benefits of amniotic membrane transplantation are supporting market expansion. Technological advancements in preservation techniques, such as cryopreservation and dehydration, are improving product availability and shelf life. Furthermore, supportive regulatory frameworks and growing investments in tissue-based therapies are accelerating adoption. With continuous innovation and increasing clinical applications, the ophthalmology amniotic membrane market is expected to witness steady growth in the coming years.
Market Scope
| Metrics | Details |
| Market CAGR | 10.22% |
| Segments Covered | By Product Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Regions Analyzed | North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world. |
| Major Companies Covered | FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, MiMedx Group, Inc, and among other major companies listed in the full report |
For more insights about the Market Request Free Sample
Ophthalmology Amniotic Membrane Market Dynamics
The market growth is driven by the rising demand for the use of amniotic membrane as a biological bandage suitable for use on the eye surface due to its properties such as thin, lightweight, elastic, and transparent. These membranes are used to treat chemical burns, cornea ulcers, and disorders leading to ulcerations during surgical procedures involving eye tissue excision.
The market is dominated by the presence of several ophthalmology amniotic membrane products. For instance, Dehydrated AmnioMatrix developed by Next Biosciences is a dry amniotic membrane with the epithelial layer of cells removed. It acts as a scaffold to which new cells can grow once placed on the wound. There is an increase in the research and development activities for developing ophthalmology amniotic membranes over the forecasted period.
The market is witnessing the filing of new patents related to the ophthalmology amniotic membrane. For instance, in May 2018, TissueTech Inc had been awarded patent 9,808,491 by the U.S. Patent Trademark Office. The patent covers the use of a gel composition comprising a morselized placental amniotic membrane and/or morselized umbilical cord as a method for treating an ocular wound or repairing damaged ocular tissue.
The increase in the number of accreditation from the different organizations and associations to several market players shall positively impact the market. For instance, in January 2020, LifeCell International received accreditation from the American Association of Tissue Banks (AATB) for its birth tissue products, including the placenta, umbilical cord, amniotic fluid, and placental amniotic membrane. This accreditation would position LifeCell as the first & only company in India and outside the US to receive this accreditation. This accreditation certifies the entire process of consent, birth tissue acquisition, processing, release, storage, and distribution.
Ophthalmology Amniotic Membrane Market Segment Analysis
The global ophthalmology amniotic membrane market is segmented into type Cryopreserved Amniotic Membrane and Lyophilization Amniotic Membrane. The cryopreserved amniotic membrane segment accounts for the highest market share due to the high usage of cryopreserved amniotic membranes in eye surgeries to heal or replace the eye tissue due to their ability to retain the histological and morphological properties of fresh tissue. Slow-rate freezing preservation techniques involve the slow freezing of the Cryopreserved amniotic membrane at –80°C using DMEM/glycerol preservation media. This slow-rate freezing preservation technique effectively retains the extracellular matrix components, such as heavy-chain hyaluronic acids, growth factors, fibronectin, and collagen, all of which promote anti-inflammatory effects and healing.
Lyophilization amniotic membrane segment is expected to witness positive market growth in 2019. Lyophilization amniotic membrane has a higher graft take rate, longer shelf life, is easier to store, and safer due to gamma irradiation than the Cryopreserved amniotic membrane.
Further, the market is also classified based on end-users into hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research and academic institutes. The hospital segment accounts for the highest market share as the hospitals are primary care settings facilitating easy treatment. A large number of patients with eye disorders visit hospitals. There is the easy availability of ophthalmology amniotic membranes in hospitals. It is further expected that this segment would maintain its dominant position over the forecasted period.
The research and academic institutes segment is expected to have positive market growth owing to rising research and development activities for ophthalmology amniotic membranes. There is an increase in investment by major companies and organizations for accelerating the development of ophthalmology amniotic membranes.
Ophthalmology Amniotic Membrane Market Geographical Share
By region, the global ophthalmology amniotic membrane market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the global ophthalmology amniotic membrane market due to many companies developing the ophthalmology amniotic membrane. The presence of a well-developed healthcare infrastructure with increased healthcare spending shall positively impact the market. According to the Committee for a Responsible Federal Budget, healthcare spending is highest in the United States than in other countries. Healthcare spending was USD 3.5 trillion in the United States in 2017.
The Asia-Pacific region is expected to have a significant market share due to increased investment in the research and development activities for ophthalmology amniotic membranes. Several multinational companies are investing in developing countries, especially India, China, and Japan. The market is witnessing technological advancement in developing ophthalmology amniotic membranes. Growing awareness, rising disposable income, and growing purchasing power shall stimulate market growth over the forecasted period.
Ophthalmology Amniotic Membrane Market Players
The global ophthalmology amniotic membrane market is highly competitive with the presence of several domestic and international players. BioTissue, Inc., MIMEDX Group, Inc., Corza Medical, Inc., NuVision Biotherapies Ltd, Akriti Ophthalmic Pvt Ltd, Integra LifeSciences Holdings Corporation, Applied Biologics, LLC, Human Regenerative Technologies, LLC, Celularity Inc., Amnio Technology, LLC are leading market players with a significant market share. Companies are following new product launches, product diversification, and market expansion strategies for increasing their market penetration.
Key Developments
- In June 2025, Celularity announced publication supporting tri-layer amniotic membrane technology for ocular surface reconstruction. The publication highlighted progress in advanced amniotic membrane design for ophthalmic applications, particularly in regenerative healing and surface repair.
- In 2025, ophthalmology experts highlighted broader use of newer products such as CAM360 alongside established cryopreserved membranes like Prokera, reflecting product innovation in comfort, handling, and ocular surface healing. This indicates ongoing commercialization and differentiation within the ophthalmic amniotic membrane segment.
**The global Ophthalmology Amniotic Membrane report will provide access to approximately 53 market data tables, 44 figures, and 178 pages
Target Audience
- Industry Investors/Investment Bankers
- Suppliers/Buyers
- Education & Research Institutes
- Manufacturers
- Research Professionals
- Emerging Companies
- Distributors
